G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia
出版年份 2014 全文链接
标题
G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia
作者
关键词
-
出版物
BLOOD
Volume 123, Issue 14, Pages 2209-2219
出版商
American Society of Hematology
发表日期
2014-02-15
DOI
10.1182/blood-2013-04-493916
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220
- (2012) D. Pauwels et al. HAEMATOLOGICA
- Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors
- (2012) E Weisberg et al. LEUKEMIA
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
- (2012) S K Metzelder et al. LEUKEMIA
- Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target
- (2012) S A Hartsink-Segers et al. LEUKEMIA
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
- (2011) T. Sato et al. BLOOD
- Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia
- (2011) Thomas Schmidt et al. CANCER CELL
- Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
- (2011) A. Parmar et al. CANCER RESEARCH
- Targeting Axl and Mer Kinases in Cancer
- (2011) A. Verma et al. MOLECULAR CANCER THERAPEUTICS
- FLT3 as a therapeutic target in AML: still challenging after all these years
- (2010) T. Kindler et al. BLOOD
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity
- (2010) A. K. Keating et al. MOLECULAR CANCER THERAPEUTICS
- Drug resistance in mutant FLT3-positive AML
- (2010) E Weisberg et al. ONCOGENE
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
- (2009) K. W. Pratz et al. BLOOD
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo
- (2009) A. Oke et al. CANCER RESEARCH
- FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML
- (2009) Ellen Weisberg et al. DRUG RESISTANCE UPDATES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now